Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - A post hoc analysis of 5796 patients

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 7, 2012, Pages 635-643

  Bytzer, P ^a   Van Zanten, S Veldhuyzen ^b   Mattsson, H ^c   Wernersson, B ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BODY MASS; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; NON EROSIVE REFLUX DISEASE; OBESITY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REFLUX ESOPHAGITIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ESOMEPRAZOLE; ESOPHAGITIS, PEPTIC; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866250337     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12007     Document Type: Article

References (24)

1. Vakil N, Veldhuyzen van Zanten S, Kahrilas P, Dent J, Jones R,. The Montreal definition and classification of gastro-esophageal reflux disease (GERD)-a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
2. Dent J,. Review article: from 1906 to 2006-a century of major evolution of understanding of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 24: 1269-81.
3. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al,. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91.
4. van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME., Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2010; 11: CD002095.
5. Donnellan C, Sharma N, Preston C, Moayyedi P., Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 2: CD003245.
6. El-Serag H, Becher A, Jones R,. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-37.
7. Boeckxstaens GE, Smout A,. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastroesophageal reflux disease. Aliment Pharmacol Ther 2010; 32: 334-43.
8. Wiklund I, Carlsson J, Vakil N,. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 2006; 101: 18-28.
9. Bytzer P,. What makes individuals with gastroesophageal reflux disease dissatisfied with their treatment? Clin Gastroenterol Hepatol 2009; 7: 816-22.
10. Chey WD, Mody RR, Izat E,. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci 2010; 55: 3415-22.
11. Becher A, El-Serag H,. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 34: 618-27.
12. Armstrong D, Talley NJ, Lauritsen K, et al,. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004; 20: 413-21.
13. Labenz J, Armstrong D, Lauritsen K, et al,. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21: 739-46.
14. Wiklund IK, Junghard O, Grace E, et al,. Quality of life in reflux and dyspepsia patients. psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998; 583: 41-9.
15. Bredenoord AJ, Hemmink GJ, Smout AJ,. Relationship between gastro-oesophageal reflux pattern and severity of mucosal damage. Neurogastroenterol Motil 2009; 21: 807-12.
16. Kahrilas PJ, Howden CW, Hughes N,. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011; 106: 1419-25.
17. Kahrilas P, Jonsson A, Denison H, Wernersson B, Hughes N, Howden C., Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10: 612-9.
18. Kahrilas P, Jonsson A, Denison H, Wernersson B, Hughes N, Howden C., Problematic regurgitation despite potent acid suppression and heartburn relief in patients with non-erosive reflux disease or reflux oesophagitis. Gut 2011; 60 (Suppl. 3): A267.
19. Fass R, Delemos B, Nazareno L, Kao R, Xiang J, Lu Y,. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease-a double-blind, placebo-controlled, randomized study. Aliment Pharmacol Ther 2010; 31: 950-60.
20. Diculescu M, Iacob R, Chira C, Mihaila D, Iacob S,. Esomeprazole in the treatment of patients with heartburn and other upper gastrointestinal symptoms, referred to primary care-results of the in-practice evaluation program in Romania. Rom J Gastroenterol 2005; 14: 9-14.
21. Nagy P, Jonsson A, Lind T, Tulassay Z,. Does body mass index have an effect on symptom relief with esomeprazole in patients with reflux esophagitis or non-erosive reflux disease? Gut 2011; 60 (Suppl. 3): A267.
22. Nagy P, Långström G, Lind T, Tulassay Z,. Does body mass index have an effect on healing rates achieved with esomeprazole 40 mg in patients with reflux esophagitis? Gut 2009; 58 (Suppl. 2): A6.
23. Jones R, Liker HR, Ducrotté P,. Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease. Int J Clin Pract 2007; 61: 1301-7.
24. Dorval E, Rey JF, Soufflet C, Halling K, Barthelemy P,. Perspectives on gastroesophageal reflux disease in primary care: the REFLEX study of patient-physician agreement. BMC Gastroenterol 2011; 11: 25.